Authors’ response to the Letter to the Editor regarding: Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations
We have carefully read the comments by Adiletta and colleagues...
Adiletta G, Baglioni S, Bettoncelli G, Bracciale P, Cazzola M, Clini EM, et al. Comments on “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations” by D’Amato et al. Multidiscip Respir Med 2021;16:757.
D'Amato G, Acanfora L, Delli Paoli L, D'Amato M. Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations. Multidisc Respir Med 2021;16:748.
Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;323:1775–6.
La gestione della malattia Covid-19. Documento di indirizzo AIPO (Associazione Italiana Pneumologi Ospedalieri) - ITS (Italian Thoracic Society). Edizioni AIPO; 2020.
Fu HY, Luo Y, Gao JP, Wang L, Li HJ, Li X, et al. Effects of short-term low-dose glucocorticoids for patients with mild COVID-19. Biomed Res Int 2020;2020:2854186.
Almas T, Ehtesham M, Khan AW, Khedro T, Hussain S, Kaneez M, et al. Safety and efficacy of low-dose corticosteroids in patients with non-severe Coronavirus disease 2019: A retrospective cohort study. Cureus 2021;13:e12544.
Liu F, Ji C, Luo J, Wu W, Zhang J, Zhong Z, Lankford S, et al. Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019. Sci Rep 2020;10:13689.
Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, et al. Persistent post-COVID-19 inflammatory interstitial lung disease: an observational study of corticosteroid treatment. Ann Am Thorac Soc 2021. Online ahead of print.
Zhagn S, Li D, Chen H, Zheng D, Zhou Y, Chen B, et al. [Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids].[Article in Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020;49:220-6.
Almas T, Hussain S, Haadi A, Ehtesham M, Hassan A, Khan AW, et al. When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19. Ann Med Surg (Lond) 2021;62:236-8.
Drago F, Gozzo L, Li L, Stella A, Cosmi B. Use of enoxaparin to counteract COVID-19 infection and reduce thromboembolic venous complications: A review of the current evidence. Front Pharmacol 2020;11:579886.
Hao C, Xu H, Yu L, Zhang L. Heparin: an essential drug for modern medicine. Prog Mol Biol Transl Sci 2019:163:1-19.
Hippensteel JA, LaRiviere WB, Colbert JF, Langouët-Astrié, CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol 2020:319:L211-7.
Italian Medicines Agency (AIFA). Low molecular weight heparins in the treatment of adult patients with COVID-19. Update: 24 November 2020. Available from: https://www.aifa.gov.it/documents/20142/1267737/Low-molecular-weight- heparins_EN_24.11.2020.pdf/fc92d837-e27a-17af-18db-9a8635fb19d5
Administrative Court of Region Lazio. Ruling n. 1557-2021. Available from: https://www.affaritaliani.it/static/upl2021/2021/0001/202101412_05.pdf
- Abstract views: 211
- PDF: 48
- HTML: 0
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.